🚀 VC round data is live in beta, check it out!
SAB Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for SAB Bio and similar public comparables like Molecular Partners, Guerbet, Tiziana Life Sciences, Compugen and more.
SAB Bio Overview
About SAB Bio
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Founded
2014
HQ
Employees
63
Website
Sectors
Financials (LTM)
EV
$82M
SAB Bio Financials
SAB Bio reported last 12-month revenue of — and negative EBITDA of ($51M).
In the same LTM period, SAB Bio generated — in gross profit, ($51M) in EBITDA losses, and had net loss of ($4M).
Revenue (LTM)
SAB Bio P&L
In the most recent fiscal year, SAB Bio reported revenue of — and EBITDA of ($29M).
SAB Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($51M) | XXX | ($29M) | XXX | XXX | XXX |
| Net Profit | ($4M) | XXX | ($34M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SAB Bio Stock Performance
SAB Bio has current market cap of $187M, and enterprise value of $82M.
Market Cap Evolution
SAB Bio's stock price is $3.92.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $82M | $187M | 0.0% | XXX | XXX | XXX | $-0.72 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSAB Bio Valuation Multiples
SAB Bio trades at (1.6x) EV/EBITDA.
EV / Revenue (LTM)
SAB Bio Financial Valuation Multiples
As of March 18, 2026, SAB Bio has market cap of $187M and EV of $82M.
Equity research analysts estimate SAB Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SAB Bio has a P/E ratio of (52.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $187M | XXX | $187M | XXX | XXX | XXX |
| EV (current) | $82M | XXX | $82M | XXX | XXX | XXX |
| EV/EBITDA | (1.6x) | XXX | (2.8x) | XXX | XXX | XXX |
| EV/EBIT | (1.5x) | XXX | (1.9x) | XXX | XXX | XXX |
| P/E | (52.1x) | XXX | (5.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SAB Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SAB Bio Margins & Growth Rates
SAB Bio's revenue in the last fiscal year grew by —.
SAB Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
SAB Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 40% | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SAB Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Molecular Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| Guerbet | XXX | XXX | XXX | XXX | XXX | XXX |
| Tiziana Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Compugen | XXX | XXX | XXX | XXX | XXX | XXX |
| Orthocell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SAB Bio M&A Activity
SAB Bio acquired XXX companies to date.
Last acquisition by SAB Bio was on XXXXXXXX, XXXXX. SAB Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SAB Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSAB Bio Investment Activity
SAB Bio invested in XXX companies to date.
SAB Bio made its latest investment on XXXXXXXX, XXXXX. SAB Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SAB Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SAB Bio
| When was SAB Bio founded? | SAB Bio was founded in 2014. |
| Where is SAB Bio headquartered? | SAB Bio is headquartered in United States. |
| How many employees does SAB Bio have? | As of today, SAB Bio has over 63 employees. |
| Who is the CEO of SAB Bio? | SAB Bio's CEO is Samuel J. Reich. |
| Is SAB Bio publicly listed? | Yes, SAB Bio is a public company listed on Nasdaq. |
| What is the stock symbol of SAB Bio? | SAB Bio trades under SABS ticker. |
| When did SAB Bio go public? | SAB Bio went public in 2021. |
| Who are competitors of SAB Bio? | SAB Bio main competitors are Molecular Partners, Guerbet, Tiziana Life Sciences, Compugen. |
| What is the current market cap of SAB Bio? | SAB Bio's current market cap is $187M. |
| Is SAB Bio profitable? | No, SAB Bio is not profitable. |
| What is the current EBITDA of SAB Bio? | SAB Bio has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of SAB Bio? | Current EBITDA multiple of SAB Bio is (1.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.